Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cognate and Terumo BCT collaborate on closed system manufacturing.
Memphis, TN September 28th, 2018 – Cognate BioServices, a leading contract development and manufacturing organization (“CDMO”) in the global cellular therapies industry, today announced a letter of intent for a collaboration agreement with Terumo BCT, a leading technology provider in the cell therapy market. Under the terms of the agreement, Cognate will incorporate Terumo BCT’s existing and future technologies into the company’s Innovation labs.
Cognate will also serve as a technology reference center for Terumo BCT’s devices (including the Quantum Cell Expansion System among others) allowing customers to access manufacturing guidance and processes and for Cognate to be a technology showcase for closed system manufacturing facilities, processes and equipment. Cognates’ facilities would also be a beta site for new technologies and their use in relevant client processes.
“Terumo BCT’s reputation for bringing automation to the cell therapy industry for apheresis and cell processing technologies is outstanding and we are excited to be a center of excellence for both our prospective and current clients in the US and abroad. One of our goals as a CDMO is to provide the experience and direction for our clients which help to improve and expedite processes in all phases. We are also pleased to expand on our existing relationship with Terumo BCT to share our innovation team’s development and manufacturing feedback from clients on current and new technologies.”
-J. Kelly Ganjei, CEO and Chairman, Cognate BioServices
About Cognate BioServices
Cognate BioServices is a fully-integrated contract bioservices organization providing the highest level of scientific and management expertise. Cognate provides full development and cGMP manufacturing services to companies and institutions engaged in the development and manufacture of cell-based products. The combination of highly experienced staff, successful track records and cGMP facilities makes Cognate one of the most qualified contract manufacturers of cell-based products in the world today. Please visit www.cognatebioservices.com for more information
About Terumo BCT
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.
Media:
Cognate BioServices
www.cognatebioservices.com
Terumo BCT
Corporate Communications
+1.303.542.5396
press@terumobct.com
Great read thanks. Hopefully when it comes out hedge funds been naked shorting a company that has a potential cure for cancer Naked shorting will be stopped.
Interesting older IV post about the phase 1 poly IVLC trial with DC vax
Koman, I'm not certain you read everything, because I mentioned UCLA has a parallel 60 patient trial that reached full enrollment in January that is testing DCVax-L with SOC by itself versus DCVax with standard of care + 1 of either 2 adjuvants.
Yes,my sense is this is part of the entire scheme set up by UCLA/FDA.
Something I just want to interject here. There is a very important variable, amongst all the obvious ones in these DCVax-L trials, and that is at some point they have to ration most patients' DCs. This creates a number of different procedures/protocols imho that make us all pull our hair out, but if humans are going to solve our own problems, we can't be weighted down in concrete precedence/thinking.
That parallel UCLA trial, despite my frequent references to it over time, has remained quietly in the background, and yet, it may in fact reveal its findings at the same time DCVax-L phase III does.
Consider that the phase 1 trial with adjuvants was sponsored by NWBO, but they are not sponsoring the second trial. Why might that be? Because SEC regulations would force disclosure at an earlier time? That's been my thinking.
Look at that trial's endpoints.
Primary Outcome Measures: Most effective combination of DC vaccine components [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ] Secondary Outcome Measures: Time to tumor progression and overall survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Yeah. I know. "6 weeks," and what's more, it's still blinded. I'll make a guess that the primary outcome at 6 weeks is based upon an immune response.
However, the previous trial design did not allow us to test which formulation of the vaccine was the most effective. This phase II study will attempt to dissect out which components are most effective together. Dendritic cells (DC) (cells which "present" or "show" cell identifiers to the immune system) isolated from the subject's own blood will be treated with tumor-cell lysate isolated from tumor tissue taken from the same subject during surgery. This pulsing (combining) of antigen-presenting and tumor lysate will be done to try to stimulate the immune system to recognize and destroy the patient's intracranial brain tumor. These pulsed DCs will then be injected back into the patient intradermally as a vaccine. The investigators will also utilize adjuvant imiquimod or poly ICLC (interstitial Cajal-like cell) in some treatment cohorts. It is thought that the host immune system might be taught to "recognize" the malignant brain tumor cells as "foreign" to the body by effectively presenting unique tumor antigens to the host immune cells (T-cells) in vivo. -- UCLA/clinicaltrials.gov.
So take that thinking one step further. Dr. Liau just gave a speech on DCVax-L that kind of centered around a patient that responded to DCVax-L + TLR-7.
You almost have to have those trials come out at the same time, don't you? P.S. I do not believe there is a crossover in the phase II trial.
Hey Etienne I was on a weekend vacation in Montreal last night
We were right at that corner
I saw the squeegee guys working.
Thats pretty cool what you believe happened
Good luck to us
Thanks Bbcbro very positive to see new trials ready to start
Exactly which leads to the conclusion that they are in the process of analysing and releasing data now.
The new line from the groups holding back NWBO is that results may never be released. Just ridiculous
Please tell me what the advantage to the company is by not unblinding Enlighten me
Thanks for the quality posts DocLogic They are appreciated more than you can tell by the responses... or lack of responses.
If you could upvote here the appreciation we feel would be more obvious.
Cheers and good luck
Something I read here today to keep the spirits up... Woodford stated that he is still all in on his investments and portfolio picks. Even though market has not agreed yet.
What I related to and respected is that he would not buy the dot com bubble like the rest of wall street lemming analysts.
Personally I started shorting Yahoo at 140 and it went to 200 Borrowed off my Mom and then my Grandmother to cover and then doubled down when Granny thought I was asking for American dollars not Canadian.
Anyway was lucky to get out alive and not put the family in poverty
.
What I respect about Woodford is that he believes in his trades .Investing in cutting edge life changing technologies. And or not following the latest wall street fad
. very hard to time the market as I have learned
Personally I think he has some honour, and if he attempted something nefarious he may well adimit it try to move on from that.
Good luck fellow dreamers and visionaries
August news would be released when holidays are over and traders back at their desks. I expect to hear topline Sept 05 at the earliest
Perhaps NWBO does not trust FDA to approve so they want England and Nice approvoal first to ensure FDA is forced into quick approvoal
Nice read thanks Sharpie
My opinion is buyout deal being worked out for last few months. NWBO will lay back on lawsuits and prosecuting the wolfpack but there will be a statement that it was acknowledged that nefarious activities occured and the perps will change the way they act.They promised.
I think Linda wants to get this therapy to patients. If she has to make a deal not to go after the rodents then so be it. She will be validated and the media will be behind her....with big pharmas nod of approvoal
Have to wait for the true story to come out in 5 years. Thats my opinion tonight anyway.
Good luck fellow dreamers and visionaries.
This submission to Nice on DCVax behalf certianly looks promising in regards to timeline to unblinding.
I would say this definitley increases chances of unblinding in August instead of November
Fingers crossed
So Lykiri, so you believe the last enrolled patients are living longer than the total group. That would make sense as to the delay in blinding. Is that your understanding? Thanks Joe
I donated. First time ever for a go fund me. Ex Avii Librarian and the rest of you should do the same
Dendreon sold again for 832 million, Company looking to open up manufacturing in Hong Kong.
Pretty amazing price for old technology.... Now what do you think we are worth with a successful trial?
Chinese are smart they want therapies that cure with no side effects.
Here is the link
https://endpts.com/with-high-expectations-on-provenge-dendreon-is-sold-again-in-832m-deal/?utm_medium=email&utm_campaign=534%20Thur%208218%20The%20scandalous%20story%20of%20a%20startup%20incubators%20ties%20to%20biotech%20analysts%20Dendreon%20sells%20for%20872M&utm_content=534%20Thur%208218%20The%20scandalous%20story%20of%20a%20startup%20incubators%20ties%20to%20biotech%20analysts%20Dendreon%20sells%20for%20872M+CID_067b8f207cbeffb9e81601043fd7a203&utm_source=ENDPOINTS%20emails&utm_term=With%20high%20expectations%20on%20Provenge%20Dendreon%20is%20sold%20again%20in%20832M%20deal
IMO what this means...if you get to 36 months you are expected to go to 88 months
Anyone in the trial that lived 36 months was evaluated. They took the number of patients that lived for 36 months added together the months they lived so far and divided by the number of patients living 36 months.
Example 30 patients lived over 36 months (this was done from an early time point years ago)
A few died from 3 to 4 years then deaths slowed. At 88 months there was still 24 patients alive. At 110 months 22 alive .
So it may be a small sample size to make the conclusion on the km curve but its still valid.
And by the way if any other drug owned by big pharma could make that statement they would be making headlines all over the world.
Good luck fellow dreamers and visionaries
What is up with Niel Woodford? Still holding his shares yes. Will he be allowed to purchase shares after announcement of sucessful trial?
Perhaps
Did he have anything to do with positive news coverage in UK? Hopefully.
If this trial is succesful I hope he can come out smelling like roses. We could use his help.
Where would we be without the 150 180 million he invested?
He is definitley not knocking NWBO
Many questions to be answered.
Good luck fellow visionaries and dreamers.
Common sense always prevails. Who in there right mind would waste time posting about a stock they say will fail?
I am here to get rich. You pleebs are here for the hourly $$
I am sure you justify your job because you believe you are doing it for your family.
But there is always something in the back of your mind that your not doing the right thing.
If your questioning your path only you can change it.
I posted that ad Thought it was in time mag
Have not seen another ad since
Hi Biotech, I saw an add in time magazine from Go boldly. They were showing a dendretic cell. I wish Go boldly would elaborate. Thanks for all your contributions
Evanstony really enjoy your posts. Thanks
Ewww wouldnt it be excellent if Mcain was asked not to reveal he was on DCVax until trial results are released...zThen he could tell the world how good he is feeling. With no side effects from treatment
Thanks Doc Logic, I dont see it as inevitable stock price will drop. I am waiting for the big unveiling and subsequent buy out. Personally would never risk selling any at this price and hope to buy cheaper. Could average down again when Linda does.
Thanks for all your contributions
So you are saying Linda may not be disclosing results until she gets more cheap shares?
If thats the case she better announce when the trial will finish (when she gets her cheap shares)
Cherry great efficaccy is great efficacy. It wont be disputed. Thats why we are waiting for overall survival. The gold standard.... And no side effects.
Any party tring to challenge if we have over 70 alive will look like morons.
Thanks Gary for your prospective,
I also believe the delay in unblinding might be a partnership or buyout.
Seen it happen before. Big Pharma can then manage all media about the trial results and how to move forward. There will be no investigation into shorting and manipulation if a big pharma buyout goes through.Linda will say she is content to see the product move to getting to patients.
Definitly a scenario worth considering.
Hi Flipper, I have definitley seen the cheap buyout with management making out very well take place.
Oh yes she offered the same terms to certian investors.
Anyway we will see if theres a buyout before full data is revealed.
Good article on how much can be charged for Right to try...
BCLI is talking about 300,000 potentially They say they have a wait list of 1000 people
https://www.bloomberg.com/news/articles/2018-06-20/the-price-to-try-a-drug-could-be-300-000-for-dying-patients
Called Nwbo headquarters today. Gave them my name and amount of shares owned.
I told the lady consensus on message board is it is time to unblind. Trial has gone on long enough.
She laughed and said she would get the message to the appropiate person.
Glad I called
Real words Doc Logic. Thanks for writing what so many here feel.
Results have to be undisputabe and fantastick.
Perhaps we are waiting for the right allies to join us.
I can see finiancing coming from a multitude of characters...
Maybe were not the only people that see the potential here.
I just got the opinion of my sister in law about how she percievied the blinded data
Little background info. She was the lead trial site administrator for the failed Astrenensza lung cancer immunotherapy trial.
She Traveled the world with my brother setting up and checking on clinical trial sites
She has always been sceptical of Nwbo
She is a very honest and moral lady.
Her words... very impressive data. Stock should be much higher. Big pharma is currently operating under a cloak of silence I see a buy out offer coming
Linda please unblind the trial now. We need topline results. You have enough cheap shares. They only way to get the manufacturing progessing and therapy to patients is to unblind now.
Thanks RK , I dont see any info in your article about how much the compay that provides the drug can charge for the drug. Great DCVax has no side effects because patients would have to pay out of pocket for side effects from the RTT drug
Phase 2 trial success of DCVac for ovarian cancer. Wonder how close this drug is to ours
http://www.b3cnewswire.com/201806031782/phase-ii-clinical-trials-of-dcvac-show-significant-benefit-for-patients-with-ovarian-and-lung-cancer.html
Thanks Evanstony, hopefully RTT helps with manufacturing and helps push FDA to approve
Just as I thought no link. Keep working on a Sunday
Sure you did ha ha
Hank this was discussed. It is not stated that a profit cannot be made on RTT
Show the link if you disagree